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Abstract The X-chromosomal-linked lysosomal storage
disorder Fabry disease can lead to life-threatening manifes-
tations. The pathological significance of the Fabry mutation
D313Y is doubted, because, in general, D313Y patients do
not present clinical manifestations conformable with Fabry
disease. This is in contrast to the analysis of the alpha-
galactosidase A activity, which is reduced in D313Y
patients. We report a comprehensive clinical, biochemical
and molecular genetic analysis of two patients with a
D313Y mutation. The alpha-galactosidase A activity was
reduced in both patients. No Fabry symptoms or Fabry
organ involvement was detected in these patients. The new
biomarker lyso-Gb3, severely increased in classical Fabry
patients, was determined and in both patients lyso-Gb3
was below the average of a normal population.
Our data for the first time not only clinically but also
biochemically supports the hypothesis that the D313Y
mutation is not a classical one, but a rare variant mutation.
Report
Fabry disease is an X-chromosomal-linked lysosomal storage
disorder caused by decreased activity of the enzyme alpha-
galactosidase A (Desnick et al. 1995). Classical Fabry disease
mainly affects three organs: the kidney, the heart and the
central nervous system (Whybra et al. 2009). This can lead
to life-threatening manifestations at end stage of the disease
including severe cardiomyopathy with arrhythmias, renal
failure and stroke (Whybra et al. 2009). Besides the classical
form of the disease, in recent years, so-called Fabry organ-
variants have been described which mainly affect only the
heart or the kidney. Moreover, some reports suggest that also
non-organ-affecting variants, which do not alter organ
function, may exist (Linthorst et al. 2010; Houge et al.
2011). These non-organ-affecting variants tend to have a
higher frequency in the normal population than the classical
private Fabry mutations, which are often only found in one
single family (Linthorst et al. 2010). The variant mutation
D313Y (located on an exon) seems to be such a mutation.
The allele frequency in the normal population of D313Y is
approximated as high as 0.5 % (Yasuda et al. 2003). Initially
the D313Y mutation was described as causing classical
Fabry disease by Eng et al. in 1993 (Eng et al. 1993),
although Eng et al. did not include extensive organ
characterisation in their study. Newer reports doubted the
pathological significance of this special mutation, even the
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possibility that D313Y is a polymorphism was discussed
(Froissart et al. 2003; Yasuda et al. 2003). In some of the
studies, the alpha-galactosidase A activity in patients with
the D313Y mutation was decreased, in others it was not
(Froissart et al. 2003; Yasuda et al. 2003; Baptista et al.
2010; Gaspar et al. 2010; Wozniak et al. 2010). Because of
the phenotypic and biochemical partly discrepant results, a
large Portuguese stroke study screening for Fabry disease
comes to the conclusion, however, that the pathogenicity of
the mutation D313Y cannot be conclusively determined
without additional information (Baptista et al. 2010).
We report a comprehensive clinical, biochemical and
molecular genetic analysis of two patients with a pure
D313Y mutation (out of our cohort of 175 Fabry patients).
The study conformed to the principles outlined in the
Declaration of Helsinki and the locally appointed ethics
committee has approved the research protocol. The referral
to our Fabry centre took place because of the query for
initiation of enzyme replacement therapy in a 20-year-old
female patient with proven D313Y mutation. The patient
had been screened for Fabry disease in another university
hospital because of skin lesions that were found on the arms
and legs, but also on the trunk and face. Her only clinical
symptom was unspecific pain manifested in her arms. A
reduced alpha-galactosidase A activity of 0.35 nmol/min/
mg protein (normal: 0.4–1.0 nmol/min/mg protein) and the
described D313Y mutation were detected. Subsequently, an
extensive family pedigree and testing of first-grade relatives
was performed. The results showed no mutation in the
mother’s gene with a normal alpha-galactosidase A activity
with 0.52 nmol/min/mg protein. The father, however, had a
D313Y mutation and a slightly reduced alpha-galactosidase
activity of 0.32 nmol/min/mg protein. We conducted a
detailed clinical analysis of the two family members with
proven mutations in our centre (Table 1). Neither the
20-year-old female nor her father (53 years old) showed
any signs or organ manifestations linked to classical Fabry
manifestation. The only clinical diagnosis which could be
made in the father was a long-lasting and excessive nicotine
abuse. In the young female, a new dermatological exami-
nation with skin biopsies gave evidence for the presence of
keratosis pilaris rubra atrophicans, but no evidence of
typical Fabry angioma. In addition to alpha-galactosidase A
activity and molecular testing, we determined lyso-Gb3 in
these two patients. For lyso-Gb3, lyso-Ceramide had been
used as reference items (Matreya LLC, Pleasant Gap, PA,
USA) and D5-Fluticasone Propionate (EJY Tech, Inc.,
Rockville, MD, USA) were used as internal standards. The
method was performed analogous to the method published
in Tanislav et al. (2011). The lyso-Gb3 in the daughter was
measured 0.22 ng/ml, which is below the average of a
normal population (around 0.4 ng/ml) (Tanislav et al.
2011). No lyso-Gb3 was detectable in her father’s blood.
The detailed analysis of our two patients provides clear
evidence that the mutation D313Y causes a pseudodefi-
ciency of the alpha-galactosidase A, not associated with
Fabry disease. Even in the 53-year-old father (an age at
which male Fabry patients often die), no Fabry-associated
manifestations could be determined. Thus, our data challenge
the usual way to establish the diagnosis in Fabry disease
(Havndrup et al. 2010; Weidemann and Niemann 2010):
When a male patient shows decreased alpha-galactosidase A
Table 1 Clinical characteristics of the two Fabry patients with the
D313Y mutation
Daughter Father




LysoGb3 (ng/ml) 0.22 0
BMI (kg/m²) 25.0 22.1
Heart rate (/min) 60 62
Blood pressure (mmHg) 115/65 116/82
Cardiac assessment
LVED wall-thickness (mm) 7 8
Left ventricular mass (g/m²) (Devereux
formula)
42 62
EF (%) 69 69
Diastolic function Normal Normal
Strain rate lateral wall (s–1)* 1.3 1.2
MRI No LE No LE
Oedema No No
Renal assessment
Creatinin plasma (mg/dl) 0.7 0.8





Transient ischaemic attack No No
Pain Yes, atypical No
Acroparaesthesia No No
Symptoms
Abnormal sweating No No
Heat or cold intolerance No No
Sudden deafness No No
Angiokeratomata 0 0
Dyspnoea on exertion No No
BMI body mass index, DTPA diethylene triamine pentaacetic acid,
EF ejection fraction, Gb3 globotriaosylceramide, GFR glomerular
filtration rate, LE late enhancement, LVED left ventricular end-
diastole, MRI magnetic resonance tomography
*Normal absolute values for systolic strain rate in the lateral wall
(regional myocardial function) > 1.1
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activity (like our male patient), the diagnosis is regarded as
proven. In female patients with borderline alpha-galactosidase
A activity (like in our female patient), genotyping with the
search for a Fabry-related mutation is demanded (Weidemann
and Niemann 2010). However, these two conditions are
perfectly met in our patients with the D313Y mutation.
Thus, our female and male patients are very good examples
that the pure assessment of the alpha-galactosidase A
activity in combination with genotyping is not sufficient
for diagnosing Fabry disease (which is especially a problem
for the future in screening studies (Linthorst et al. 2010;
Houge et al. 2011). In contrast, lyso-Gb3 seems to be the
biochemical key for the clinical classification of an unclear
alpha-galactosidase A mutation. In 2008, the new bio-
marker lyso-Gb3, a degradation product of the stored lyso-
Gb3, was proposed for the first time to be a hallmark of
Fabry disease by Aerts et al. (2008). They could show that
lyso-Gb3 was elevated in patients with classical Fabry
disease. Although the pathophysiological role of lyso-Gb3
in Fabry disease is not elucidated and mechanisms in Fabry
organ complications involve multiple mechanisms beyond
lyso-Gb3 (Schiffmann 2009; Auray-Blais et al. 2010;
Brakch et al. 2010), the results of the study by Aerts et al.
suggested that lyso-Gb3 plays an important role as a factor
in the pathogenesis and progression of the disease (Aerts
et al. 2008). Moreover, the same group also demonstrated
little to normal values in atypical mutations (van Breemen
et al. 2011). In our two patients, only a very low or no lyso-
Gb3 at all was detectable, indicating that there was no
classic organ involvement in these patients – as proven by
our clinical characterisation. The explanations for this
might be as follows: (1) In general, mutated and often
misfolded alpha-galactosidase A proteins do not reach the
lysosomes but are stuck in the endoplasmatic reticulum.
However, there is evidence that the D313Y mutated alpha
galactosidase A proteins do reach the lysosomes (Yasuda
et al. 2003). (2) In addition, a normal activity of the D313Y-
mutated protein was found in the lysosomes and a pseudo-
reduced activity in plasma by Yasuda et al. (2003). This is
due to the pH dependency of the D313Y-mutated alpha
galactosidase A protein which results in a normal activity in
the acid lysosomes and a reduced activity in the neutral
plasma. (3) The mutation is located at some distance from
the active site of the protein and the dimer interface. (4) The
asparagine 313 has expressed its carboxyl-end to the
exterior (hydrophilic fraction), while the rest of the side
chain is in a hydrophobic environment (Froissart et al.
2003; Yasuda et al. 2003). Therefore, Yasuda et al.
concluded that an exchange from asparagine to tyrosine
could be tolerated without greater damage for protein
activity (Yasuda et al. 2003). This all leads to a residual
high activity of alpha-galactosidase A in the lysosomes
leading to only small amounts of Gb3 storage. Because
Lyso-Gb3 is a degradation product of Gb3 the residual
activity of alpha-galactosidase A also leads to only a small
amount of lyso-Gb3, which indicates a non-organ-affecting
variant.
In conclusion, our data strengthen the hypothesis that the
D313Y mutation is not a classical phenotype mutation but a
rare variant mutation located on an exon as described by
Froissart, Yasuda and Desnick. For the first time this
assumption can also be supported biochemically by the
measurement of the new marker lyso-Gb3. There are
several other mutations (e.g. R112H, c.593C4T) where a
discrepancy between positive standard diagnostic tests and
lack of manifest disease have been shown (Aerts et al.
2008; Houge et al. 2011). It is a task for the future to
perform lyso-Gb3 and other biochemical testing in various
Fabry mutations, which are described as atypical in the
literature. Of course, we cannot deny – due to the small
number of our patients’ cohort, the main limitation of our
study – that there might be some patients with D313Y,
where the biochemical analysis (enzyme activity and
lyso-Gb3) might argue for a mild phenotype. This has to
be discussed since it might be possible that the clinical
spectrum of resulting consequences in some mutations
reflects a continuum instead of a yes/no spectrum. The
biochemical analysis of Fabry patients is even more
complicated by the missing standardisation of measure-
ments of the biomarkers involved in the diagnosis of Fabry
disease. The standardisation is a major task for the future.
Limitations: The small number of our patient’s cohort,
leading to the diagnostic consequences explained in the last
paragraph of the discussion.
Take Home Message
Our Lyso-Gb3 analysis indicates that the alpha-galactosidase
A mutation D313Y is not clinically relevant for Fabry disease
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